Characteristics | Items | N (%) |
---|---|---|
Sex | Female | 26 (18.4%) |
 | Male | 112 (79.4%) |
Age | Mean | 64 |
 | Median (range) | 66 (30–87) |
 | St.dev | 11 |
Portal Vein Thrombosis | No | 64 (46.4%) |
 | Yes | 74 (53.6%) |
Tumor location | Right lobe | 57 (41.3%) |
 | Left lobe | 10 (7.2%) |
 | Bilateral lobe | 71 (51.4%) |
Stage T | T1 | 8 (5.8%) |
 | T2 | 10 (7.2%) |
 | T3 | 120 (86.9%) |
Stage N | N0 | 114 (82.60%) |
 | N1 | 24 (17.4%) |
Stage M | M0 | 116 (84.1%) |
 | M1 | 22 (15.9%) |
AJCC Stage | I | 7 (5.1%) |
 | II | 9 (6.5%) |
 | III | 83 (60.1%) |
 | IV | 39 (28.3%) |
Okuda Stage | I | 31 (22.4%) |
 | II | 107 (77.6%) |
BCLC Stage | A | 9 (6.5%) |
 | B | 29 (21.0%) |
 | C | 100 (72.5%) |
Child-Pugh Stage | A | 96 (69.6%) |
 | B | 42 (30.4%) |
Hepatitis | No | 19 (13.8%) |
 | B | 71 (51.4%) |
 | C | 43 (31.2%) |
 | B and C | 5 (3.6%) |
Initial Alpha-fetoprotein (?g/L) | Median (range) | 11481 (2.4 – >58300) |
Initial white blood count (kU/?L) | Median (range) | 5.9 (2.7 – 15.6) |
Initial haemoglobin level (g/dL) | Median (range) | 12.8 (7.0 – 19.0) |
Initial GPT level (U/L) | Median (range) | 50.0 (8.8 – 396.0) |
Initial total bilirubin level (mg/dL) | Median (range) | 0.9 (0.3 – 8.5) |
Initial tumor volume (cm3) | Median (range) | 516 (28 – 3621) |
Total liver volume (cm3) | Median (range) | 1587 (548 – 5489) |
Dose prescription | 45Gy | 16 (11.6%) |
 | 60Gy | 114 (82.6%) |
 | 66Gy | 8 (5.8%) |